Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 22, 2008, Pages 5916-5919

  Hur, Wooyoung ^a   Velentza, Anastasia ^b   Kim, Sungjoon ^b   Flatauer, Laura ^b   Jiang, Xinnong ^c   Valente, David ^b   Mason, Daniel E ^b   Suzuki, Melissa ^d   Larson, Brad ^d   Zhang, Jianming ^c   Zagorska, Anna ^e   DiDonato, Michael ^b   Nagle, Advait ^b   Warmuth, Markus ^b   Balk, Steven P ^c   Peters, Eric C ^b   Gray, Nathanael S ^c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d INVITROGEN CORPORATION   (United States)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Bmx; EFGR; Irreversible inhibitors; Quinazoline scaffold; Reactive cysteine; Tec family kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; CANERTINIB; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PELITINIB; PROTEIN KINASE; PROTEIN KINASE BMX; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ARTICLE; BINDING SITE; DRUG CROSS REACTIVITY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN MODIFICATION; SEQUENCE ALIGNMENT;

ANIMALS; CYSTEINE; MICE; MOLECULAR STRUCTURE; MORPHOLINES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 55249109749     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.062     Document Type: Article

References (13)

1. Sharma S.V., Bell D.W., Settleman J., and Haber D.A. Nat. Rev. Cancer 7 (2007) 169
2. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J.A., McNamara D.J., Nelson J.M., Sherwood V., Smaill J.B., Trumpp-Kallmeyer S., and Dobrusin E.M. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 12022
3. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., McGinnis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., and Haber D.A. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 7665
4. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs III W.H., Edeen P.T., Floyd M., Ford J.M., Grotzfeld R.M., Herrgard S., Insko D.E., Mehta S.A., Patel H.K., Pao W., Sawyers C.L., Varmus H., Zarrinkar P.P., and Lockhart D.J. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11011
5. Campos S., Hamid O., Seiden M.V., Oza A., Plante M., Potkul R.K., Lenehan P.F., Kaldjian E.P., Varterasian M.L., Jordan C., Charbonneau C., and Hirte H. J. Clin. Oncol. 23 (2005) 5597
6. Pan Z., Scheerens H., Li S.J., Schultz B.E., Sprengeler P.A., Burrill L.C., Mendonca R.V., Sweeney M.D., Scott K.C., Grothaus P.G., Jeffery D.A., Spoerke J.M., Honigberg L.A., Young P.R., Dalrymple S.A., and Palmer J.T. ChemMedChem 2 (2007) 58
7. Melnick J.S., Janes J., Kim S., Chang J.Y., Sipes D.G., Gunderson D., Jarnes L., Matzen J.T., Garcia M.E., Hood T.L., Beigi R., Xia G., Harig R.A., Asatryan H., Yan S.F., Zhou Y., Gu X.J., Saadat A., Zhou V., King F.J., Shaw C.M., Su A.I., Downs R., Gray N.S., Schultz P.G., Warmuth M., and Caldwell J.S. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 3153
8. Cohen M.S., Zhang C., Shokat K.M., and Taunton J. Science 308 (2005) 1318
9. Wissner A., Floyd M.B., Johnson B.D., Fraser H., Ingalls C., Nittoli T., Dushin R.G., Discafani C., Nilakantan R., Marini J., Ravi M., Cheung K., Tan X., Musto S., Annable T., Siegel M.M., and Loganzo F. J. Med. Chem. 48 (2005) 7560
10. Jiang X., Borgesi R.A., McKnight N.C., Kaur R., Carpenter C.L., and Balk S.P. J. Biol. Chem. 282 (2007) 32689
11. Qiu Y., Robinson D., Pretlow T.G., and Kung H.J. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3644
12. Pan S., An P., Zhang R., He X., Yin G., and Min W. Mol. Cell. Biol. 22 (2002) 7512
13. Yao X.R., and Scott D.W. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 7946